Tenax’s Phase 3 Trial for Levosimendan Fails Primary Endpoint in PH-HFpEF
Event summary
- Tenax Therapeutics’ Phase 3 LEVEL trial of oral levosimendan in PH-HFpEF failed to meet its primary endpoint of improving 6-minute walk distance vs. placebo.
- The trial also missed the key secondary endpoint of improving Kansas City Cardiomyopathy Questionnaire (KCCQ) total symptom score.
- Subgroup analyses showed a beneficial treatment effect in patients with greater disease burden, supported by clinically meaningful changes in cardiac biomarkers and pulmonary hemodynamics.
- Tenax plans to request a Type C Meeting with the FDA to discuss revisions to the ongoing registrational development of levosimendan for PH-HFpEF.
The big picture
The failure of the LEVEL trial is a significant setback for Orion’s license partner Tenax Therapeutics, as it complicates the regulatory pathway for oral levosimendan in PH-HFpEF. The broader implications include potential delays in bringing this treatment to market and increased scrutiny on the development of therapies for heart failure with preserved ejection fraction. Orion’s proprietary focus on pain and oncology may remain unaffected, but the outcome underscores the high-risk nature of cardiovascular drug development.
What we're watching
- Regulatory Strategy
- Whether Tenax can secure FDA and EMA support for revised development plans following the trial failure.
- Subgroup Analysis
- How the identified beneficial effects in patients with greater disease burden will shape future clinical strategies.
- Execution Risk
- The pace at which Tenax can pivot its development path for levosimendan given the Phase 3 setback.
Related topics